Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | momelotinib | Myelofibrosis | Pending | |||
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
| Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Zevalin | Ibritumomab tiuxetan | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Doptelet | avatrombopag | severe thrombocytopenia associated with chronic liver disease (CLD) | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
| Imbruvica | Ibrutinib | Not filed | ||||
| Demylocan | decitabine | Myelodysplastic Syndromes | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : May 13, 2024